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Abstract 
Background and Objectives: Depression is the second leading cause of 
disability, worldwide, and increasing access to its effective/preferred treatment 
requires more attention. Behavioural activation and time-intensive treatment delivery 
both show promise in this regard, yet research into their combination is limited. This 
study aimed to investigate the feasibility, effectiveness, and acceptability of time-
intensive behavioural activation (BA) for depression. Methods: Eight adults with 
major depressive disorder were recruited from three outpatient IAPT services in 
London. The study employed a single case experimental design with multiple 
baselines. All participants completed time-intensive BA, consisting of up to seven 
twice weekly sessions with daily prompting in-between and three optional booster 
sessions. Idiographic, standardised and process measures of depression 
symptomatology were collected. Results: Treatment recruitment and retention 
indicated that the intervention was feasible. Visual and statistical analyses showed 
that relative to baseline, 6 out of 8 participants made significant improvements in all 
idiographic symptoms of depression following the intervention. According to 
standardised measures of depression, four out of eight participants were considered 
treatment responders. Five participants completed follow-up measures and the 
majority of progress was maintained after the withdrawal of the intervention. The 
intervention was also considered highly acceptable by participants and therapists.  
Limitations: Conclusions cannot be drawn about the generalizability or the long-term 
durability of the findings. Conclusions: Overall this study provides new, but tentative 
evidence highlighting the potential of time-intensive BA as a feasible, effective and 
acceptable treatment for some adult outpatients with depression. The findings now 
warrant further, more rigorous evaluation of the treatment.  
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1. Introduction  
Depression is the second leading cause of disability worldwide (Ferrari et al., 
2013), and its ubiquitous burden is costly (Bloom et al., 2011). Despite the 
availability of a range of evidence-based treatments for depression (NICE, 2009) and 
the Increasing Access to Psychological Therapies (IAPT) initiative (DOH, 2008) in 
England the efficacy of psychological treatments for depression appear to have 
reached a plateau (Cuijpers, 2015). Response rates following depression treatments 
within IAPT are 55% (Richards & Borglin, 2011), and, on average, 17.5% of 
depressed clients drop out of treatment (Cooper & Conklin, 2015). Substantial 
numbers of depression cases remain undetected (Glover, Webb, & Evison, 2010), and 
many practical barriers to effective treatment remain, including characteristics of 
depression itself (e.g., pessimism), time constraints, and personal responsibilities 
(e.g., child care and work schedules) (Mohr et al., 2010).  
While antidepressant medication (ADM) and cognitive behavioural therapy 
(CBT) have demonstrated the most convincing empirical support to date (NICE, 
2009), behavioural activation has been suggested to hold particular promise as an 
accessible and disseminable treatment for depression (Kanter, Puspitasari, Santos, & 
Nagy, 2012). Indeed, its most common variants, Martell, Addis and Jacobson’s (2001) 
behavioural activation, (herein referred to as BA), and the briefer behavioural 
activation treatment for depression (herein referred to as BATD; Lejuez, Hopko, 
LePage, Hopko & McNeil, 2001) are found to be effective when disseminated across 
diverse settings populations and treatment formats (Dimidjian, Barrera, Martell, 
Munoz & Lewinsohn, 2011).   
1The abbreviations BA and BATD will be used to refer to specific versions of behavioural activation. 
The unabbreviated term will be used for the general category of approaches.  
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Dobson et al. (2008) found that BA had lower drop-out rates and more durable 
effects than ADM, and a recent randomised controlled trial (RCT) found that BA 
produced comparable results to CBT even if delivered by less highly trained 
professionals than CBT requires, and that at 12 months post-treatment it is more cost-
effective than CBT (Richards et al., 2016). 
Increasing treatment intensity is a potential means for enhancing treatment 
efficacy that is increasingly being explored. Regression analyses have demonstrated 
that faster overall recovery is significantly associated with more frequent 
psychological treatment delivery (Erekson, Lambert, & Eggett, 2015).  Time-
intensive psychological interventions, operationalized here as treatment delivered 
more frequently and concentrated over a shorter period of time than the traditional 
weekly 50-minute session, have demonstrated efficacy in the treatment of PTSD 
(Ehlers et al., 2014), OCD (Storch et al., 2007) and specific phobias (Zlomke & 
Davis, 2008). Number, frequency, and duration of sessions have varied widely, 
making it difficult to draw general conclusions regarding how best to structure 
intensive treatment. However, because depression and anxiety treatments include key 
elements that are functionally similar (see Hopko, Lejuez, Ruggiero, & Eifert, 2003b 
for a comparison of behavioural activation and exposure) it is reasonable to assume 
that time-intensive BA could have positive effects for some individuals. BA itself is 
already recommended to be delivered twice a week for the first three to four weeks, 
and then once a week thereafter (NICE, 2009). However, this recommendation is not 
followed consistently in clinical practice (Dimidjian, Martell, Addis, Herman-Dunn, 
& Barlow, 2008).  
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 Time-intensive treatment for depression has not been investigated to 
the same extent as it has been for anxiety. One meta-regression analysis concluded 
that effectiveness of depression treatment was more strongly related to session 
intensity (number of sessions a week) than general treatment quantity (Cuijpers, 
Huibers, Ebert, Koole & Andersson, 2013); delivering two sessions rather than one a 
week was associated with increased treatment effect size (g = 0.45). However, only 
six studies included in this analysis had delivered behavioural activation. In addition, 
the findings were based on planned treatment parameters rather than the 
characteristics of the treatment actually provided and so did not provide a clear-cut 
basis for associating particular therapy parameters (number, frequency and duration of 
sessions) with different outcomes. Cuijpers et al., 2013 concluded that the potential 
gain from optimal pacing, and particularly intensifying, of existing therapies is a more 
auspicious target of research than developing and testing new modalities for 
depression, although they note that there is a likely lower limit such that “no one 
would probably consider treating depression in one week” (p. 11). However, 
optimizing intensity coupled with greater specificity of knowledge within BA about 
the temporal sequencing of activation relative to symptom change (e.g., Santos et al., 
2017) offers the prospect of maximizing efficient deployment of service delivery.  
 There is some evidence, though with limitations, for the efficacy of a single 
90-minute BATD session relative to no treatment (Gawrysiak, Nicholas, & Hopko, 
2009) and waitlist controls (Nasrin, Rimes, Reinecke, Rinck, & Barnhofer, 2017). 
One study that did not find support for the single session significantly reducing 
depression symptoms in comparison to a waitlist control, proposed that future 
research should include short telephone calls between the therapist and client,  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
to prompt activation (Read, Mazzucchelli, & Kane, 2016).   
Time-intensive behavioural activation has been more commonly researched in 
inpatient settings, where, as length of stay is reduced, session frequency tends to be 
higher. One RCT demonstrated BATD’s efficacy, in comparison to a supportive 
psychotherapy control condition, when delivered to 25 participants via 20-minute 
sessions, three times a week, over a two-week period (Hopko, Lejuez, Lepage, 
Hopko, & McNeil, 2003a). However, there was a lack of an empirically validated 
control condition, and treatment adherence was not assessed. More recently, a 
rigorous multiple baseline single case experimental design (SCED) investigated the 
efficacy of a time-intensive behavioural treatment for depression based on a synthesis 
of BA and BATD (Folke et al., 2015). Six inpatients with depression were 
randomised to different baseline lengths followed by daily 20 - 30 min therapy 
sessions over five consecutive days. Five of the six showed reliable change in self-
reported and depression symptomatology and four of six on clinicians’ ratings, with 
one fewer demonstrating clinically significant change on each measure. Participants 
rated the treatment as highly satisfying. However, there was potential bias stemming 
from non-random recruitment of participants and delivery of therapy by the first 
author of the study. There are also several general limitations evident in this group of 
studies, including their small sample sizes and lack of follow-up data to examine 
maintenance of gains. Further, none of the studies used structured clinical interviews 
to diagnose MDD, and participants tended to have comorbidities and were receiving 
multiple inpatient treatments concurrent with their behavioural activation, potentially 
confounding the findings. 
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Despite more rigorous existing evidence of BA’s efficacy (Richards et al., 
2016), particularly within adult outpatient settings (Kanter et al., 2010), and most 
treatment of depression occurring therein, this review found no examples of studies 
investigating the effects of time-intensive BA in outpatient settings. Given the 
implication that time-intensive BA for depression could enhance treatment access and 
effects; this gap in the literature is worth addressing. 
Therefore, the aims of this study were to explore whether or not time-intensive 
BA was (a) a feasible intervention, (b) had an effect on idiographic measures of 
depression symptoms, (c) was associated with reliable and clinically significant 
change in standardised and process measures of depression, (d) maintained its effects 
over a follow-up period, and (e) was an acceptable treatment.  
A multiple baseline single case experimental design (SCED) was used. SCEDs 
entail monitoring change within participants through repeated measurement of 
outcomes across different study phases (Kazdin, 1982), but also capture individual 
differences between participants (Morley, 2015a).  They are a robust method for 
testing causal mechanisms of treatments as they enable participants to act as their own 
controls. Randomising participants to multiple baselines increases experimental 
control over potential extraneous threats to validity, such as maturation (Kratochwill 
et al., 2010). 
It was hypothesised that following the intervention, participants would show 
improvements in their idiographic, standardised and process measures of depression 
symptomatology. Improvement was operationalised as making significant declines on 
idiographic measure ratings (according to Tau statistics), or reliable change (Jacobson 
& Traux, 1991) on standardised and process measures. 
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2. Material and Methods 
2.1 Participants  
Participants seeking treatment for depression were recruited from three 
London IAPT services. Initially only two services were approached, but later a third 
site was added. Sixty consecutive clients presenting for treatment of depression, 
within the recruitment period, were offered the opportunity to take part in the study as 
a treatment option. Twenty-three of these clients  were interested in taking part in the 
study, and were screened. Only nine of these clients met the inclusion criteria and no 
exclusion criteria, and so were invited to be participants, eight of whom then 
consented to take part (Figure 1). The one eligible participant who declined taking 
part could no longer attend sessions due to returning to work. All participants were 
either unemployed or still in education (Table 1).  
The study received ethical approval from the UK Central London Research Ethics 
Committee.  
2.1.1 Inclusion criteria 
(1) Age 18 or over;  
(2) Primary diagnosis of MDD as assessed by the Structured Clinical Interview for 
MDD (First, Williams, Karg, & Spitzer, 2015); 
(3) Sufficient command of English to comprehend instructions and measures; 
(4) A score of ≥ 10 on the Patient Health Questionnaire (PHQ-9; Kroenke & Spitzer, 
2002); 
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(5) A score of ≥ 25 on the MADRS (Montgomery & Åsberg, 1979); 
(6) No psychopharmacological treatment or on a stable dose for six weeks prior to the 
study, with the type and dosage unaltered; 
(7) Ability to travel to treatment at the time-intensive rate.  
2.1.2 Exclusion criteria 
(1) Major suspected comorbid diagnosis of severe disorder (e.g., personality disorder 
or substance dependency) according to screening (which included use of the 
Standardised Assessment of Personality – Abbreviated Scale [SAPAS; Moran, Leese, 
Lee, Walters, Thornicraft, & Mann, 2003] and clinical judgement; 
(2) Acutely suicidal; 
(3) Concurrent additional psychotherapy; 
(4) Diagnosis of a long-term condition that would prevent attendance (e.g., requiring 
hospitalisation). 
Participants were not offered any compensation for taking part in the study.  
 
 
 
Approached: N = 60 
Service 1: n = 20    
Service 2: n = 39 
Service 3: n = 1                                                                              
 
 
   
 
Declined/excluded: N =. 32 
Unable to attend time-intensively: n = 23 
Requested CBT: n = 2 
No longer seeking treatment: n= 2 
Did not wish to take part in research: 
 n = 5 
Accepted information sheet:  
N = 28  
Service 1: n = 15 
Service 2: n = 12 
Service 3: n = 1                                           
 
Declined/excluded: N = 5  
Unable to attend time-intensively: n = 3 
Requested CBT: n = 2 
Unable to contact: n = 1 
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. Materials and methods 
Completed: N = 8 
Service 1: n = 5 
Service 2: n = 2 
Service 3: n = 1                                                                              
Excluded: N = 14 
Currently in treatment: n = 1 
Suspected personality disorder 
according to SAPAS: n = 2  
Self-reported alcohol/drug 
dependence: n = 2 
Primary anxiety: n = 2 
Below MADRS cut-off: n = 1  
Requested CBT: n = 4  
Did not meet MDD criteria: n = 1 
Unable to attend: n = 1 
Appropriate and assessed: N = 9                                          
Service 1: n = 5 
Service 2: n = 3 
Service 3: n = 1                                       
Participants who dropped out: N = 0                                           
 
Consented and randomised to 
baseline lengths: N = 8                                        
Service 1: n = 5 
Service 2: n = 2 
Service 3: n = 1                                       
Dropped out: N = 1                                            
Returned to work. 
Interested and screened: N = 23 
Service 1: n = 12 
Service 2: n = 10 
Service 3: n = 1                                           
Figure 1. Flow of recruitment and participation 
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Table 1 Clinical summary of participants 
P Service Sex Age Ethnicity Marital 
status 
Education 
Level 
Employment 
status  
Duration 
of  
problem 
Previous 
episodes  
Previous treatment 
(year) 
 
Current 
medication 
(dose, 
duration)  
Comorbidity 
 
A 
(PA) 
1 F 37 White 
Portuguese 
Single Undergraduate 
degree 
Unemployed  2 
months 
2 1.CBT for anxiety  
(2015) 
None GAD 
LTC 
B 
(PB) 
1 F 60 White 
British 
Divorced O-Levels Retired 10 
months 
3 1. Psychiatric 
hospitalisation for 
depression (1981) 
2. Counselling  
(1990) 
Citalopram 
(20 mg, 12 
months) 
LTC 
C 
(PC) 
2 F 49 White 
Mixed 
European 
Separated Undergraduate 
degree 
Unemployed 4 years 4 1.CBT for low 
mood (2015) 
Citalopram 
(20 mg, 9 
months) 
GAD 
LTC 
D 
(PD) 
2 F 31 Black 
British / 
Caribbean 
In a 
Relationship 
NVQ Long-term 
Sick Leave 
4 
months 
4 1.CBT for low 
mood (2011) 
Fluoxetine 
(20 mg, 10 
weeks)  
Secondary 
anxiety and 
panic 
attacks 
E 
(PE) 
1 M 21 White 
British 
 
Single A-levels Unemployed 2 
months 
3 1.CBT for 
depression (2014) 
Citalopram 
(10 mg, 8 
weeks) 
None 
F 
(PF) 
1 F 27 White 
European 
Single Undergraduate 
degree 
Student  6 
months 
2 None None Secondary 
anxiety 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
G 
(PG) 
 
3 F 28 White 
British 
Cohabiting 
with Partner 
Postgraduate 
degree 
Student 1 year 3  1.Counselling for 
bereavement  
(2014) 
None GAD 
H 
(PH) 
1 M 56 White 
British 
In a 
Relationship 
A-levels Unemployed 6 
months 
2 1.Counselling  
(1992) 
 
2. Counselling 
(2016) 
Fluoxetine 
(40 mg, 5 
months) 
GAD 
LTC 
Mean 
(SD) 
  
39 
(14.57) 
    
11 
months 
(14.27) 
3 (0.83)    
Note. GAD = generalized anxiety disorder; LTC = long-term physical health condition; NVQ = National Vocational Qualification; P = 
participant; SD = standard deviation. Some details have been changed, to protect participant anonymity.
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2.2 Design 
The study employed an A1BA2 SCED. The A1 phase was the multiple baseline 
phase with participants randomly allocated to baseline lengths of seven, 14 or 21 
days. Phase B was the intervention phase (time-intensive BA) followed by a three-
week follow-up period of symptom monitoring (A2).  
2.2.1 Therapists 
Six, out of 23 therapists approached, were involved in the study. Reasons for 
not taking part in the study were working part-time (n = 4), having a full case-load (n 
=10), and not yet being fully qualified (n = 3). Inclusion criteria included that all 
therapists were either qualified Clinical Psychologists or High-Intensity Cognitive 
Behavioural Therapists. They had received training in BA as part of their degrees but 
were also required to attend a half-day BA training session.  
2.3. Measures 
Clinician rated, and self-report measures of depression were collected. 
2.3.1. Idiographic measures 
The primary outcome measures were visual analogue scales (VASs) of 
depression, rumination, avoidance, a participant chosen main symptom of depression, 
and an encapsulated belief. Encapsulated beliefs consisted of statements summarising 
the meaning of participants’ experiences of depression. Scores ranged from 0 to 100, 
with higher scores indicating higher symptomatology or frequency of belief. VASs 
were completed daily across all three study phases.  
2.3.2 Standardized measures 
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Standardized measures of depression severity were completed weekly throughout 
the baseline, intervention and follow-up phases of the study, to provide global context 
to the interpretation of idiographic measure outcomes. These were: 
(a) The Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery 
& Åsberg, 1979). The MADRS is a 10-item clinician-rated scale measuring 
depression symptoms over the past week. Each item is rated on a seven-point 
Likert scale from 0 (indicating ‘normal’ or ‘no difficulties’) to 6. The summed 
score range is 0–60, and higher scores reflect greater symptomatology. The 
measure has shown high inter-rater reliability between .89 and .97, and 
significant convergent validity (Montgomery & Åsberg, 1979).  
(b) The Patient Health Questionnaire (PHQ-9; Kroenke & Spitzer, 2002). The 
PHQ-9 is a 9-item self-report measure of depression symptoms, usually from 
the past two weeks, yet here participants were asked to refer to the past week. 
Each item is scored from 0 (‘not at all’) to 3 (‘nearly every day’), and summed 
scores range from 0 to 27, with higher scores reflecting greater 
symptomatology. The measure has high reported internal consistency 
(Cronbach’s α = .89) and convergent validity (Kroenke, Spitzer, & Williams, 
2001).  
2.3.3 Process measures 
The Behavioural Activation for Depression Scale - Short Form (BADS-SF; 
Manos, Kanter & Luo, 2011). The BADS-SF is a 9-item self-report scale 
measuring activation and avoidance over the past week used to determine 
whether BA is having an impact on activity levels. It was completed weekly 
over the baseline and intervention phases. Items are rated from 0 (“not at all”) 
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to 6 (“completely”). Total scores range from 0 to 54. Higher scores represent 
more activation. It has good internal consistency (Cronbach’s α = .82) and 
demonstrated construct validity (Manos et al., 2011).  
2.3.4    Ending measures 
The following measures were completed after participants finished their final 
session: 
(a) The Client Satisfaction Questionnaire (CSQ; Larsen, Attkisson, Hargreaves, 
& Nguyen., 1979). The CSQ is an 8-item self-report measure of clients’ 
satisfaction with services. Items are rated on different four-point Likert scales 
and are summed to give a total score ranging from 8 to 32, with higher scores 
indicating greater satisfaction. Reported Cronbach’s α ranges from .83 to .93, 
indicating excellent internal consistency.  
(b) Participants and therapists were also asked to rate how acceptable they found 
the intervention, on VASs, ranging from 0 (“not at all”) to 100 (“completely”).  
(c) The Quality of Behavioural Activation Scale (QoBAS; Dimidjian, Hubley, 
Martell & Herman, 2016). The QoBAS is a 14-item scale assessing 
therapists’ use of BA strategies. Items are rated on a seven-point Likert Scale 
from 0 (“poor”) to 6 (“excellent”), with a score of 3 indicating satisfactory BA 
skill quality. Higher scores indicate greater treatment quality. The measure is 
not yet validated but is currently the primary measure of BA fidelity in use.  
 
2.4. Intervention  
Time-intensive BA for depression was delivered, based on Martell et al.’s 
(2013) clinicians’ guide. BA entails carrying out idiographic functional analyses of 
participants’ depressive behaviours (including cognitive processes such as 
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rumination), as well as the contextual contingencies of reinforcement maintaining 
them. It then promotes engagement in activities and contexts that promote behaviours 
that counteract depression and that are consistent with the client’s values and goals. 
Activity scheduling is regularly restructured according to individual formulations to 
promote completion of scheduled activities.  
Three independent assessors used the QoBAS (Dimidjian et al., 2016) to 
assess one randomly selected session from five participants (meaning that 7% of all 
sessions were assessed). The mean QoBAS score was 3.74 (SD = 0.75), exceeding the 
satisfactory treatment competence threshold. In addition, 80% of assessed sessions (n 
= 4) met minimum criteria of a rating of 3.00. Reliability between the assessor’s 
ratings was also acceptable, with an intra-class correlation of .83.   
2.5. Procedure 
Clients seeking treatment for depression identified as suitable for BA, were 
sent information sheets. Those willing and eligible to participate attended a study 
assessment and were randomly allocated to an intervention start time. The therapist 
and participant then worked collaboratively to build a functional analysis. Participants 
identified and completed their idiographic measures and were given a timetable of 
their scheduled sessions and outcome measures to be completed. 
Therapists aimed to deliver a minimum of 10 and maximum of 13 hours of 
face-to-face BA. The initial seven sessions were twice weekly, to allow ample activity 
monitoring and activation implementation, with the initial three sessions 
recommended to last for two hours, and the last four recommended to last one hour. 
The inclusion of a break in longer sessions was suggested to counteract fatigue. Three 
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optional booster sessions were offered and recommended to take place at one, two and 
four weeks after a participant’s seventh session.  
On each weekday, in-between face-to-face sessions, and up until booster 
sessions began, therapists or an Assistant Psychologist (see Supplementary Table 1) 
telephoned, texted, or emailed participants for short ‘prompting’ conversations, 
whenever they could. Prompting was intended to as a method of contingency 
management, to demonstrate therapists’ dedication to participants, to give participants 
direction, and to positively reinforce progress, morale, motivation, treatment 
compliance, and the therapeutic relationship. This is in line with one of the core 
principles of BA (Martell et al., 2010), which is for therapists to act as a “coach”. It 
also meant that participants who had limited support networks still had a regular form 
of reinforcement outside of session times. 
The frequency of prompts was not pre-defined, and was dependent on need 
and feasibility. However, therapists logged prompting durations and aimed to keep 
each prompting telephone conversation to ten minutes long. Participants could 
respond to text messages or emails whenever they wanted to but understood that 
therapists would attempt to respond within 24 hours.  
In line with previous research, participants who received eight hours of 
clinician contact were deemed treatment completers (Richards et al., 2016). Where 
possible, symptom monitoring continued for three weeks post treatment, and all 
participants were offered a clinical review after follow-up to assess need for further 
treatment. If so, participants could continue sessions with their existing therapist or 
necessary onward referrals were made. 
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2.6 Analysis  
Idiographic data were first graphed using Microsoft Excel, and then visual 
analyses were conducted to determine whether or not the intervention was effective. 
Change in the central tendency (reflecting the level of symptom change), trend 
(reflecting the strength of symptom change) and variability (reflecting the stability of 
symptom change) of idiographic symptoms were assessed, across each phase, in 
accordance with visual analysis guidelines (Kazdin, 1998). Statistical analysis of 
idiographic data was conducted using Tau-U (Parker, Vannest, Davis, & Sauber, 
2011), which tests for the percentage of non-overlap between study phases, 
controlling for baseline trend. Weighted averages, forming omnibus effect sizes 
across all of the participants, were also calculated for each idiographic measure 
(http://www.singlecaseresearch.org/calculators/tau-u). 
The MADRS, PHQ-9 and BADS-SF were used to identify the number of 
participants who displayed reliable and clinically significant change (Jacobson & 
Traux, 1991) from baseline to end of treatment and follow-up. Comparisons of pre 
and post-intervention scores were based on single or average baseline scores (where 
participants had two). Post-BA and follow-up scores were calculated from final 
session and final follow-up session scores, respectively. Criterion “a” was used for 
reaching reliable and clinically significant change on the MADRS and BADS-SF, 
whereas criterion “b” was used for the PHQ-9 (Jacobson & Traux, 1991). Clinical and 
non-clinical population means and standard deviations, from existing research data, 
were used to calculate the criteria (Cunningham, Wernroth, von Knorring, Berglund, 
& Ekselius, 2011; Dimidjian et al., 2017; McMillan, Gilbody, & Richards, 2010). 
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Participants were classified as treatment responders if they met criteria for both 
reliable and clinically significant change on one or both measures of depression.  
3. Results  
3.1. Treatment feasibility  
Table 1 provides a brief clinical summary of each participant.  
All participants were considered treatment completers. In total, 68 of 76 
sessions offered were attended (89%). Variation in attendance and prompting 
frequencies resulted in variations in treatment durations across participants 
(Supplementary Table 1).  On average, participants received nine sessions (SD = 
1.41), or 11 hours and 20 minutes of face-to-face therapist contact (SD = 1.62). All 
participants received different types and frequencies of prompting (see Supplementary 
Table 1). However, an average of 17 prompting text messages were sent to 
participants being prompted via text alone, and an average of six prompting telephone 
calls were made to participants being prompted over the telephone. Due to limited 
data, it was not possible to calculate average prompting frequencies for participants 
receiving both text and telephone call prompts, or email prompts. 
3.2. Idiographic symptom outcomes  
Figures 2 to 5 display raw data, lines of central tendency and trend for 
participants’ idiographic depression and rumination ratings. All eight participants 
showed some fluctuation in idiographic depression ratings over the baseline phase, 
but participants A, B, E, and G showed slight upward trends. During the intervention 
phase, all participants except participant C (whose symptoms remained relatively 
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unchanged), showed declines in trend and central tendencies, relative to baseline, and 
statistical analyses indicated that they experienced significant reductions in depression 
(Table 3). Declines in trend were not consistent. The change in trend was more 
noticeably pronounced and rapid for participant B. Participant E showed a more 
stepped decline after losing a friend to suicide. Participants F, G and H showed more 
gradual declines, and participant A’s trend was less clear. Four participants who 
provided follow-up data did not show significant changes in their depression scores 
following the withdrawal of the intervention. Conversely, Participant D’s scores 
showed reversed upward trend over the last two weeks of her treatment, and this 
continued to increase at follow-up.  
All eight participants also showed fluctuation in their rumination ratings over 
the baseline phase, and participants B, E, F and G’s rumination showed slight 
increasing trends. During the intervention phase, all participants showed declines in 
levels of rumination, relative to the baseline phase; however, these only reached 
significance for six participants (Table 4). Patterns of change seen for depression 
ratings were reflected in rumination ratings; however participant C showed small 
declines in levels of rumination over the intervention phase, which increased again at 
follow-up, and participant F experienced further significant reduction in her 
rumination following the withdrawal of the intervention.   
VAS’s of avoidance, encapsulated beliefs, and chosen symptoms of 
depression also showed that the majority of participants (n = 5, 6, and 7, respectively) 
experienced significant reductions in symptoms, following the onset of the 
intervention, and that the majority of participants who provided follow-up data 
reported maintained or continued improvements (Supplementary Tables 2 to 4).  
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Weighted averages of non-overlap of data between phases (Tables 3 to 4 and 
Supplementary Tables 2 to 4) indicated that, across all participants, all idiographic 
symptoms showed significant declines between baseline and intervention phases, with 
depression and encapsulated beliefs decreasing the most. Between the intervention 
and follow-up phases, all symptom ratings reflected decline in the intervention’s 
effects, but the proportion of depression ratings that increased reached significance. 
When combining data from intervention and follow-up phases, relative to baseline, 
significant declines were still evident on all idiographic symptom ratings.  
Of note, all participants reported experiencing ongoing life-stressors, which 
may have influenced the high variability of data, and biased weighted average 
calculation. For example, PD’s pattern of symptom change may have been influenced 
by her experience of a traumatic event at approximately day 49. As the only 
participant to show significant deterioration in depression at follow-up, her outcomes 
may have influenced the significant increase in the weighted average of non-overlap 
of depression scores between intervention and follow-up.  Therefore, individual 
outcomes, as opposed to weighted averages were considered for the basis of drawing 
conclusions (Parker & Vannest, 2012).  
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Figure 2. Depression VAS data from participants A, B, C and E.  
 
Note. Raw data =        ; central tendency (broadened median) =        ; trend (running 
median) =        ;         = session; * = life stressor. Participant E lost a friend to suicide 
and reported that it made him feel less abnormal. Different calculations of central 
tendency and trend plots were chosen according to Morley’s visual analysis 
guidelines (Morley, 2015b).  
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Figure 3. Depression VAS data from participants G, H, D and F.  
 
Note. Raw data =        ; central tendency (broadened median) =        ; trend (running 
median) =        ;         = session; * = life stressor. Participant D experienced a trauma, 
Participant G experienced a relationship breakdown and participant H stopped taking 
his medication. Different calculations of central tendency and trend plots were chosen 
according to Morley’s visual analysis guidelines (Morley, 2015b).  
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Figure 4. Rumination VAS data from participants A, B, C and E.  
 
Note. Raw data =        ; central tendency (broadened median) =        ; trend (running 
median) =        ;         = session; * = life stressor. Participant E lost a friend to suicide 
and reported that it made him feel less alone abnormal. Different calculations of 
central tendency and trend plots were chosen according to Morley’s visual analysis 
guidelines (Morley, 2015b).  
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Figure 5. Rumination VAS data from participants G, H, D and F.  
 
Note. Raw data =        ; central tendency (broadened median) =        ; trend (running 
median) =        ;         = session; * = life stressor. Participant D experienced a trauma, 
Participant G experienced a relationship breakdown and participant H stopped taking 
his medication. Different calculations of central tendency and trend plots were chosen 
according to Morley’s visual analysis guidelines (Morley, 2015b).  
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Table 3 Summary of tau analyses comparing idiographic depression ratings across 
the study phases. 
Participant Comparison Tau SD Tau p value 90% CI 
A A x B -0.51 0.25 .04* [-0.91, -0.10] 
B x C  -0.18 0.17 .28 [-0.46, 0.09] 
A x (B+C) -0.55 0.24 .02* [-0.94, -0.16] 
B A x B -0.94 0.24 <.001*** [-1.00, -0.55] 
B x C  0.25 0.15 .10 [0.00, 0.50] 
A x (B+C) -0.96 0.23 <.001*** [-1.00, -0.58] 
C A x B -0.31 0.23 .19 [-0.70, 0.08] 
B x C  -0.14 0.15 .36 [-0.39, 0.11] 
A x (B+C) -0.36 0.23 .11 [-0.74, 0.01] 
D A x B -0.55 0.18 <.01** [-0.84, -0.26] 
B x C  0.80 0.15 <.001*** [0.55, 1.00] 
A x (B+C) -0.21 0.17 .21 [-0.49, 0.07] 
E A x B -0.66 0.24 <.01** [-1.00, -0.26] 
F A x B -0.60 0.18 <.001*** [-0.89, -0.31] 
B x C  0.34 0.18 .05 [0.05, 0.63] 
A x (B+C) -0.65 0.17 <.001*** [-0.94, -0.37] 
G A x B -0.83 0.24 <.001*** [-1.00, -0.45] 
H A x B -0.80 0.26 <.01** [-1.00, -0.35] 
Weighted 
average 
A x B -0.64  <.001*** [-0.80, 0.00] 
B x C  0.22  <.01** [0.08, 0.36] 
A x (B+C) -0.53  <.001*** [-0.72, -0.35] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = confidence 
interval; SD = standard deviation; Weighted averages = combined effect-size; * = p <.05; ** 
= p <.01; *** = p <.001 
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Table 4 Summary of tau analyses comparing idiographic rumination ratings across 
the study phases. 
Participant Comparison Tau SD Tau p value 90% CI 
A A x B -0.59 0.25 .02* [-0.99, -0.18] 
B x C -0.00 0.17 .98 [-0.28, 0.27] 
A x (B+C) -0.59 0.24 .02* [-0.98, -0.20] 
B A x B -0.97 0.24 <.001*** [-1.00, -0.59] 
B x C 0.23 0.15 .13 [-0.02, 0.487] 
A x (B+C) -0.98 0.23 <.001*** [-1.00, -0.60] 
C A x B -0.45 0.23 .06 [-0.83, -0.06] 
B x C 0.10 0.15 .52 [-0.15, 0.34] 
A x (B+C) -0.46 0.23 .04* [-0.84, -0.09] 
D A x B -0.43 0.18 .01* [-0.72, -0.15] 
B x C 0.53 0.15 <.001*** [0.28, 0.77] 
A x (B+C) -0.29 0.17 .09 [-0.57, -0.01] 
E A x B -0.45 0.24 .06 [-0.85, -0.06] 
F A x B -0.48 0.18 <.01** [-0.77, -0.19] 
B x C -0.46 0.18 <.01** [-0.76, -0.17] 
A x (B+C) -0.55 0.17 <.01** [-0.83, -0.27] 
G A x B -0.78 0.24 <.001*** [-1.00, -0.40] 
H A x B -0.62 0.26 .02* [-1.00, -0.20] 
Weighted 
average 
A x B -0.59  <.001*** [-0.74, -0.40] 
B x C 0.10  .18 [-0.05, 0.23] 
A x (B+C) -0.55  <.001*** [-0.74, -0.38] 
Note. A = Baseline phase; B = Intervention phase; C = Follow-up phase; CI = confidence 
interval; SD = standard deviation; Weighted averages = combined effect-size; * = p <.05; ** 
= p <.01; *** = p <.001 
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3.3. Reliable and clinically significant change 
At the end of the intervention phase, seven participants had made reliable 
change on the MADRS (Table 5). Of these, three participants also met criteria for 
clinically significant change (B, C, & E). At follow-up, participant F continued to 
improve, whereas participant C experienced deterioration in her symptoms. Of those 
who completed follow-up data (n = 5), three participants met criteria for reliable 
change (A, B, & F), of whom two also met criteria for clinically significant change (B 
& F).  At the end of the intervention phase, four participants’ scores demonstrated 
reliable change on the PHQ-9, three of whom also met criteria for clinically 
significant change (PB, PE, & PG).  At follow-up, participants A and F showed 
continued improvement and overall three participants met criteria for reliable and 
clinically significant change (A, B, & F). Of note, some participants’ responses 
clearly differed between the MADRS and PHQ-9. By the end of the intervention 
phase, all participants apart from participant C demonstrated reliable change in their 
BADS-SF scores. However, only participants B and E met criteria for clinically 
significant change on the BADS-SF.  Following the assumption that overall treatment 
responders were those who demonstrated reliable and clinically significant change on 
one or both standardised measures of depression, half of the participants (B, C, E & 
G) were considered treatment responders at the end of their treatment, and three 
(60%) were considered treatment responders at follow-up (A, B & F). 
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Table 5 Summary of reliable and clinically significant change in standardised outcomes  
Participant MADRS 
Baseline  
MADRS  
End of 
treatment  
MADRS 
Follow-up  
 
PHQ-9 
Baseline  
PHQ-9  
End of 
treatment  
PHQ-9 
Follow-up  
 
BADS-SF 
Baseline  
BADS-SF 
 End of 
treatment  
A 39 23RC 25RC 15 13 10CSC 7 28RC 
B 31 2CSC 2CSC 10 0CSC 0CSC 19 42CSC 
C 39 9CSC 41 19 17 17 6 5 
D 36 36 37 16 17 16 21 32RC  
E 30 5CSC n/a 19 7CSC n/a 12 43CSC 
F 53 19RC 14CSC 14 9 6CSC 20 30RC 
G 45 18RC n/a 25 6CSC n/a 4 15 
H 37 26 RC n/a 17 11RC n/a 18 26 
Note. BAD-SF = Behavioural Activation Scale - Short Form (range: 0-54); MADRS = Montgomery Åsberg Depression Rating Scale (range: 0-60); PHQ-9 = Patient 
Health Questionnaire (range: 0-27); Reliable change (RC) and clinically significant change (CSC) indicated by Jacobson & Traux, 1991. 
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3.4. Client satisfaction and acceptability of the treatment  
According to the CSQ, participants reported high treatment satisfaction (M = 
27.86, SD = 4.49). Treatment acceptability ratings were also above average for both 
participants (M = 81.43, SD = 21.16) and therapists (M = 66.67, SD = 16.33), though 
noticeably higher for participants.  
4. Discussion  
Overall, this multiple baseline SCED has demonstrated that, time-intensive 
BA was feasible, and that, for the majority of participants (n = 5 to 7) time-intensive 
BA was associated with significant improvements in idiographic symptoms of 
depression. Seven participants made reliable change on at least one standardised or 
process measure of depression, and at the end of their treatment, four participants 
were considered treatment responders. Most participants (n = 3 or 4) who completed 
follow-up measures demonstrated either maintenance or improvement of progress on 
both idiographic and standardised measures of depression. Finally, treatment 
satisfaction and acceptability were rated as above average. As improvement on 
idiographic, standardised, and process outcome measures was shown for some, but not 
all participants, the research hypothesis is only partially accepted.  
The findings add to the existing body of literature that supports the 
effectiveness of one session or time-intensive behavioural activation (Folke et al., 
2015; Gawrysiak et al., 2009; Hopko et al., 2003a; Nasrin et al., 2017), but extends 
previous findings to BA (Martell et al., 2001; as opposed to BATD), delivered via 
multiple therapists, and to participants who met criteria for MDD. Promising findings 
might be explained by behavioural models of depression (Ferster, 1973; Lewinsohn, 
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1974) and BA’s mechanism of extinguishing unhelpful behaviours that maintain 
depression, while increasing engagement in pleasant activities and response-
contingent positive environmental reinforcement (Martell et al., 2001). However, 
specific mechanisms of change were not analysed here and require further 
investigation.  
Importantly, the study’s response rates are comparable to levels of responders 
obtained from the most recent non-inferiority trial of BA versus CBT (64%; Richards 
et al., 2016), and general depression treatment response rates found within IAPT 
services (55%; Richards & Borglin, 2011). These similarities could potentially be 
explained by the studies targeting similar UK populations and settings, or the limited 
sample size in the current study. However, the findings raise questions, which require 
further research, over whether time-intensive BA could be as effective as existing, 
empirically supported and recommended pacing of BA. As this study delivered less 
than the recommended amount of BA (NICE, 2009), yet still yielded mostly positive 
results, the findings support previous evidence to suggest that increasing treatment 
intensity promotes faster overall recovery (Erekson et al., 2015). It is foreseeable 
therefore, though not proven, that delivering time-intensive treatment could have 
scope for reducing service waiting list times.  
It is interesting that level of treatment response, as well as which participants 
were considered responders, differed on the MADRS and the PHQ-9 at follow-up. 
Though moderators of effects were not examined here, discrepancies between these 
clinician and self-report rated measures could be explained by reporting bias, 
clinicians and participants having different standards for outcomes, or variation in the 
content and weighting of items of the MADRS and PHQ-9 (Cuijpers, Li, Hofmann & 
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Andersson, 2010), not to mention measurement error. Still, the discrepancies support 
evidence that clinician and self-report rated measures are not equivalent (Uher et al., 
2012). 
It was surprising that only two participants met criteria for clinically 
significant change in activation levels on the BADS-SF. However, these findings 
were consistent with those of Folke et al., (2015) who found that, despite their entire 
sample meeting reliable change on the BADS-SF, none made clinically significant 
change. Though only hypothetical at this point, it may be that our time-intensive BA 
does not allow enough between-session time for some participants to practice therapy 
skills to a sufficient level for clinically significant change. 
Considering that attrition from existing depression treatments and BA studies 
has been higher than found here (Cooper & Conklin, 2015; Richards et al., 2016), the 
current finding of high treatment retention is encouraging, and tentatively suggests 
that delivering this BA format could discourage drop-out. However, the number of 
participants and therapists that were considered eligible or willing to participate in the 
study was limited by the inclusion/exclusion criteria. Some of the similarities of the 
participants’ demographic characteristics (e.g., all being out of work and having had 
multiple previous episodes of depression) may also be a result of the 
inclusion/exclusion criteria, but these individuals could represent those most able to 
adhere to time-intensive BA. For example, time-intensive BA may be less feasible for 
working participants. In fact, a large proportion of participants approached to take part 
in the study did not have time to attend treatment time-intensively. This indicates that 
some persons with depression might prioritise not needing to take much time out of 
their existing routines to receive treatment and may also be indicative of the stigma 
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that continues to surround mental health.  
          Given that seven out of eight participants had received previous psychological 
therapy, it may be that time-intensive BA was attractive as a new and potentially 
faster treatment for recurrent depression, rather than simply as being more accessible. 
Clinicians intending to evaluate time-intensive BA should assess clients’ motivations 
and remain vigilant to identify those potentially seeking a ‘quick fix’. 
          The finding that some referrals declined involvement in the study due to a 
preference to receive CBT, suggests that the lay population may be less aware of BA 
and evidence suggesting its advantages in comparison to other treatments (Dimidjian 
et al., 2006; Dobson et al., 2008; Ekers et al., 2008; 2014; Richards et al., 2016; 
Sturmey, 2009), which this paper promotes, and could be promoted in future. It is 
understandable that treatments, when less well known and novel, might initially be 
adopted at a lower frequency. 
Finally, low therapist recruitment rates, and therapists rating the acceptability 
of the intervention as lower than the participants did, suggests that IAPT may not be 
the most feasible setting for time-intensive treatment or efficacy research to take 
place. Components of the treatment design, such as daily prompting, may become 
overwhelming for therapists within certain settings. Services should carefully consider 
whether or not they can support time-intensive interventions or research into their 
efficacy. We encourage services to consider creative ways of enhancing how ‘user-
friendly’ the treatment is , for example, by setting up text or email prompts to be sent 
automatically, protecting therapists session preparation time, and making time-
intensive therapists exempt from other responsibilities of equal weighting. 
Undoubtably, person-centred approaches will need to be adopted to consider the 
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needs of the therapist and client, and discussion of costs and funding within the 
resource confines of each service would be necessary before trying out this new 
treatment modality. Therefore, the feasibility of time-intensive BA requires further 
research. Still, if time-intensive BA was adopted with high efficiency, and clients 
were treated faster (Erekson et al., 2015), one might envisage that in the long-run it 
would produce a corresponding reduction in workload for participating therapists. 
The study findings are limited by only five participants completing a short 
follow-up phase, restricting conclusions that can be drawn about the treatment’s 
durability. In addition, the generalizability of the findings is limited by the study’s 
strict inclusion criteria, small, homogenous sample size, and only recruiting 
participants and therapists from three London IAPT services. Specifically, this meant 
that the sample was mainly made up of white females who were out of work, and the 
therapists were working within less flexible service structures. The reliability of 
collected data was subject to self-report biases, and experimenter bias where clinician-
rated measures were not inter-rated for reliability.  Furthermore, treatment fidelity 
cannot be assumed, as only five session tapes were assessed. Lastly, the non-
concurrent treatment design is subject to the effects of confounding variables (e.g., 
maturation), reducing the study’s internal validity. Indeed, participants’ differing 
treatment sequences and reported stressors might have predicted some variation in 
outcome measures.  
Future research should aim to rectify the limitations of the current study, 
primarily by replicating it across different samples and settings, and extending the 
follow-up phase. Considering that patterns of change on idiographic, standardised and 
process measures, of the same concept, were not always congruent, future research 
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should continue to collect all three outcome modalities. Within larger studies 
regression analyses should be conducted to determine whether or not treatment 
characteristics (e.g., duration, session number, session spacing, and prompting), 
service characteristics (e.g., IAPT or non-IAPT), participant characteristics (e.g., 
history, comorbidity and life-stressors), and therapist characteristics (e.g., experience 
and number) predict treatment responses. Coding frameworks should also be used to 
determine and track specific (e.g., prompting levels) and non-specific (e.g., 
therapeutic relationship strength) mechanisms of change that occur in each session, 
their temporal relationships to outcomes, and whether or not they are crucial to 
recovery following time-intensive BA. Qualitative research investigating reasons 
behind acceptability ratings should also be conducted. Such findings could then be 
used to guide the development of an optimized time-intensive BA. In the longer-term 
future, RCTs should be conducted to determine the efficacy and cost-effectiveness of 
different time-intensive BA designs in comparison to each other (e.g., 12 hours of BA 
delivered over one week in comparison to 12 hours of BA and prompting delivered 
across two weeks), control and/or recommended active control conditions (e.g., 
weekly BA or time-intensive CBT for depression). We anticipate that effectively 
treating depression via time-intensive treatment might still require longer treatment 
durations than some anxiety disorders have done; however, addressing these 
hypotheses to optimize time-intensive treatment would be worthwhile. Importantly, 
future research should adopt a shared definition of ‘time-intensive’, and treatment 
‘responder’ in a bid to move towards standardisation of terminology and outcomes. 
Conclusions  
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In summary, the current study provides new and tentative evidence 
highlighting the potential of time-intensive BA as a feasible, acceptable, and effective 
intervention for some, though not all, adult outpatients with depression. This 
constitutes an essential step in attempting to increase patient choice and access to 
depression treatments. The current findings now warrant further exploration in order 
to be substantiated. Once such further research has been completed, we will be more 
able to determine whether or not this treatment approach can be effectively 
disseminated within outpatient settings to promote the well-being of the population.  
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Highlights 
• Eight participants with MDD completed time-intensive behavioural activation.  
• Six participants made significant improvements in their idiographic symptoms.  
• Four participants were considered treatment responders. 
• Follow-up data showed that treatment effects were mainly maintained. 
• Participants and therapists considered the intervention to be acceptable. 
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